Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent And Sanegene Collaborate to Develop siRNA for Hypertension

publication date: Dec 27, 2023

Suzhou Innovent Biologics and Sanegene Bio, a Suzhou-Boston RNA company, will collaborate to co-develop SGB-3908, a siRNA drug candidate targeting angiotensinogen to treat hypertension. SGB-3908 is an IND-enabling stage candidate developed on SanegeneBio's proprietary LEAD™ (Ligand and Enhancer Assisted Delivery) platform. The two companies will be jointly responsible for developing SGB-3908 to a specific stage. At that point, Innovent can exercise its exclusive option to acquire development, manufacturing and commercialization rights to SGB-3908. If Innovent exercises the option, SanegeneBio will be eligible to receive milestone payments and tiered royalties. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital